Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

ACE inhibitors ‘protect against pneumonia’

Angiotensin-converting enzyme inhibitors, but not angiotensin receptor blockers, reduce the risk of pneumonia, findings from a meta-analysis show.

16 Jul 2012

Harmonizing prescription drug plans can help save millions of dollars

Taxpayers could save millions of dollars if hospitals and provincial governments harmonized their prescription drug plans, new research suggests.

28 Jun 2012

Full results from Derma Sciences’ DSC127 Phase 2 trial on diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that full results from its successful Phase 2 clinical trial with the investigational drug DSC127 in patients with diabetic foot ulcers will be published on July 5th in the July 2012 issue of Wound Repair and Regeneration.

28 Jun 2012

First clinical trial to test cardiac drug regimen for DMD

The first landmark randomized clinical trial for a cardiac drug regimen in Duchenne muscular dystrophy (DMD) is testing whether earlier treatment can stop or slow down heart damage that usually kills people with the disease.

27 Jun 2012

Maternal factors associated with fetal growth restriction

A Japanese study has found that maternal rather than fetal factors are associated with fetal growth restriction. A comparison of maternal and fetal angiotensin-converting enzyme genotypes with the size of babies at birth found evidence of this connection.

27 Jun 2012

Home BP monitoring ‘could help guide dosing, titration’

Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.

19 Jun 2012

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.

15 Jun 2012

Vitamin D deficiency may be an important risk factor for erectile dysfunction

A paper just published hypothesizes that vitamin D deficiency may be an important risk factor for erectile dysfunction (ED).

7 Jun 2012

ACE inhibitors or ARBs could treat and prevent PTSD

Traumatized people who take a class of common blood pressure medications tend to have less severe post-traumatic stress symptoms, researchers have found.

2 May 2012

UMKC School of Medicine receives $400,000 gift to establish Pulmonary Fibrosis Research Program

The University of Missouri-Kansas City has received a $400,000 gift to establish a pulmonary fibrosis research program at the UMKC School of Medicine. The gift comes from the estate of the late Mary K. Geldmacher, a retired St. Louis school teacher who suffered from pulmonary fibrosis and passed away in 2009. Pulmonary fibrosis is the formation or development of excess fibrous connective tissue in the lungs, commonly described as “scarring of the lung.”

26 Apr 2012

Losartan may not increase risk of all-cause mortality in heart failure patients

Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.

11 Apr 2012

No added benefit of aliskiren-amlodipine fixed drug combination for hypertension

The fixed drug combination of aliskiren and amlodipine (trade name: Rasilamlo-) was approved in April 2011 for the treatment of people with hypertension in whom aliskiren or amlodipine alone has an insufficient effect.

23 Mar 2012

Heart Failure Congress 2012 to take place from May 19-22

Four days of scientific sessions will be devoted to the latest advances and controversies in heart failure at this year's Heart Failure Congress 2012. The latest results from drugs and devices trials will be announced at the meeting.

21 Mar 2012

New recovery protocol treats heart failure patients with LVADs

Some patients with advanced heart failure caused by cardiomyopathy, the deterioration of function of the heart muscle, are benefitting from a new recovery protocol at the University of Louisville and Jewish Hospital, a part of KentuckyOne Health.

13 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

Women with chronic heart failure survive longer than their male counterparts

Women with chronic heart failure survive longer than their male counterparts, according to a large analysis of studies comprising data on more than 40,000 subjects. The analysis represents the largest assessment of gender and mortality risk in heart failure - and provides evidence which many randomised trials have failed to do because they have been dominated by male patients.

8 Mar 2012

High blood pressure due to stress maybe due to the immune system

If stress is giving you high blood pressure, blame the immune system. T cells, helpful for fighting infections, are also necessary for mice to show an increase in blood pressure after a period of psychological stress, scientists have found.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

Initial stent implantation does not appear to improve outcomes for patients with stable CAD

A meta-analysis of eight previously published clinical trials suggests that initial stent implantation for patients with stable coronary artery disease is not associated with improved outcomes compared with initial medical therapy for prevention of death, nonfatal heart attacks, unplanned revascularization or angina, according to a study published in the Feb. 27 Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Feb 2012